E Fund Management Co. Ltd. Acquires 655 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

E Fund Management Co. Ltd. raised its position in United Therapeutics Corporation (NASDAQ:UTHR) by 24.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,290 shares of the biotechnology company’s stock after purchasing an additional 655 shares during the quarter. E Fund Management Co. Ltd.’s holdings in United Therapeutics were worth $1,014,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Dunhill Financial LLC raised its position in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 50 shares during the last quarter. Sound Income Strategies LLC bought a new position in United Therapeutics in the first quarter valued at about $49,000. State of Wyoming bought a new position in United Therapeutics in the fourth quarter valued at about $62,000. Curat Global LLC bought a new position in United Therapeutics in the first quarter valued at about $63,000. Finally, Natixis bought a new position in United Therapeutics in the fourth quarter valued at about $85,000. 94.08% of the stock is currently owned by institutional investors.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $300.00, for a total value of $3,300,000.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $11,034,300. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard Giltner sold 3,036 shares of the firm’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the sale, the director directly owned 19,384 shares of the company’s stock, valued at $5,613,606.40. This trade represents a 13.54% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,681 shares of company stock worth $24,618,359. 10.30% of the stock is currently owned by insiders.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $309.72 on Thursday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The stock has a 50 day moving average price of $295.40 and a two-hundred day moving average price of $310.03. The stock has a market capitalization of $13.97 billion, a PE ratio of 12.09, a price-to-earnings-growth ratio of 4.57 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period last year, the business posted $5.85 EPS. The company’s revenue was up 11.7% on a year-over-year basis. Research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Bank of America lowered their price objective on United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a research report on Wednesday, June 11th. HC Wainwright set a $400.00 price objective on United Therapeutics and gave the stock a “buy” rating in a research report on Thursday, July 31st. Morgan Stanley lowered their price objective on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. Finally, UBS Group raised their price objective on United Therapeutics from $385.00 to $415.00 and gave the stock a “buy” rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $382.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.